ARK Genomic Revolution ETF vs Global X FTSE Southeast Asia ETF — how do they compare? ARK Genomic Revolution ETF trades at $44.53, while Global X FTSE Southeast Asia ETF trades at $21.47. Which is the better fit depends on your goals.
| ARKG | ASEA | |
|---|---|---|
Sector | Sector/Thematic | Sector/Thematic |
52-Week High | $44.55 | $21.53 |
52-Week Low | $24.02 | $16.86 |
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
ASEA trades at $21.53, up 1.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows uniform support and resistance at $21. Key financial ratios are unavailable, but a dividend of $0.41 is scheduled for July 2026. Recent business developments and earnings data are not provided, limiting fundamental assessment.
The outlook is cautiously optimistic due to strong technical momentum, though the absence of current financial metrics and news increases uncertainty. Investment opportunity hinges on upcoming financial disclosures, while risks include data gaps and market volatility. Investors should await earnings reports for clearer valuation insights.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →